Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Next Previous
Trial Profile

Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antisense EGFR gene therapy; Cetuximab
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 16 Jun 2021 Biomarkers information updated
  • 20 Sep 2012 Planned initiation date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov. (NCT01592721).
  • 20 Sep 2012 Planned initiation date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov. (NCT01592721).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top